First test: can new Drug-Radiation combo fight tough breast cancer?
NCT ID NCT03109080
Summary
This early-stage study tested the safety of combining the drug olaparib with standard radiation therapy in patients with advanced triple-negative breast cancer. The trial involved 24 women whose cancer had not responded fully to prior chemotherapy or had returned after surgery. Researchers aimed to find the highest safe dose of olaparib that could be given alongside radiation to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY SIDE EFFECT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 75005, France
Conditions
Explore the condition pages connected to this study.